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3D-QSAR modelsAbstract Twenty-eight novel 1,5-disubstituted-2(1H)-pyridone derivatives were designed and syn-
thesized for discovering more potent anti-lung cancer agents combined with anti-fibrotic profiles.
The in vitro antiproliferative activities of the derivatives against A549 and NIH3T3 cell lines were
tested by MTT assays. The majority of the tested analogues exhibited equivalent or an improved
anti-lung cancer activity. Prominently, compound 4l displayed the best potency and selectivity
toward A549 with an IC50 value of 20 lM, nearly comparable to the positive control cisplatin
(IC50 = 10 lM) and even superior to the lead compound 22 (IC50 = 130 lM). Simultaneously,
compound 4l showed significant inhibitory activity against NIH3T3 (IC50 = 55 lM), which may
contribute to hindering the proliferation of lung cancer cells fundamentally. What is more, the
3D-QSAR models established on the activity data may provide new insights into the design of novel
2(1H)-pyridone derivatives and lay a theoretical foundation for further studies of promising anti-
lung cancer activity with the maintenance of anti-fibrotic effect.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Lung cancer is the markedly leading cause of cancer-related
mortality worldwide, with over 228,000 new cases and more
than 1159,000 deaths reported in 2014 in the United States
(Ali et al., 2015). Approximately 85% of lung cancer patients
can be histologically classified as non-small cell lung cancer
(NSCLC) and the overall 5-year survival rate of this highly
aggressive disease is only 15% (Roldan et al., 2014). The high
prevalence and mortality rate are mainly attributable to the
difficulty of early diagnosis and lung tumors’ elevated potential
722 Q. Xu et al.for local invasion as well as metastasis to distant tissues and
organs (Moses et al., 2014). At present, treatments for lung
cancer include surgery, radiation therapy, chemotherapy, and
targeted therapies (Wei-Ting et al., 2015). Nevertheless, the
outcomes are limited and do not show to be of sufficient ben-
efit in reality despite advances in tumor biology research. The
efficacy of conventional anti-lung cancer modalities has
already encountered a plateau because of lacking selectivity
or intrinsic and acquired resistance (Ying-Rui et al., 2012).
On this account, it has become imperative for identifying more
effective anti-lung cancer strategies with minimal toxicity. To
our knowledge, the occurrence of fibrosis typically resulting
from inflammation or damage is capable of obliterating archi-
tecture and function of the involved organs or tissues such as
lung, liver and kidney (Krenning et al., 2010; Huang et al.,
2011). Contemporarily, it is suggested that pulmonary fibrosis
shares similar pathological ground to lung cancer, and certain
tissues that undergo fibrosis subsequently are susceptible to
carcinogenicity, thus aggravating the burden of lung cancer
(Kenneth et al., 2006). Given that inhibiting the onset and pro-
gression of pulmonary fibrosis can ultimately reduce the for-
mation of benign tumors and cancers, it makes great sense
to develop specific anti-lung agents possessing anti-lung cancer
property combined with an anti-fibrotic potential, which also
seems to be of much interest as new therapeutic anti-lung can-
cer agents in future.
Pirfenidone (PFD, Fig. 1A) has emerged as a valuable
agent for use in patients with idiopathic pulmonary fibrosis
(IPF) (Azuma, 2010). This drug can inhibit the progression
of fibrosis and collagen synthesis to ameliorate bleomycin-
induced and cyclophosphamide-induced lung fibrosis (Iyer
et al., 2000; Spond et al., 2003). Fluorofenidone (AKF-PFD,
Fig. 1A), an analogue of pirfenidone, has been discovered by
our group in programs engaged for anti-fibrosis agents. This
compound shows comparable anti-fibrotic potency to pir-
fenidone, while it possesses a better pharmacokinetic profile
(e.g. with a longer half-life) and less toxicity in rats (Yuan
et al., 2011). In further optimization work, considerable efforts
were undertaken by our research group to obtain more active
and metabolically stable candidates in the past years.
Accordingly, two series of novel 5-substituent-2(1H)-
pyridone derivatives were synthesized and evaluated for the
antiproliferative activity against NIH3T3 cells (Jun et al.,
2012). As a result, compound 5b (Fig. 1) exhibited as highly
potent anti-fibrosis agents with an IC50 of 80 lM about 34-
fold of AKF-PFD (IC50 = 2750 lM). Besides, SAR analysis
elucidated that introduction of a benzyl group at N-1 position
of pyridone nucleus could enhance anti-fibrotic activity.
Literature survey reveals that molecules containing a moiety
of pyridone show a broad spectrum of promising pharmaco-
logical properties such as anti-cancer (Kyoung et al., 2008;
Gretchen et al., 2009; Li et al., 2012; Jee et al., 2015), anti-
diabetic (Dean et al., 2014), anti-bacterial (Manoranjan
et al., 2014; Nisheeth et al., 2013), anti-pruritic (Masahide
et al., 2012), anti-oxidant (Semple et al., 2003), anti-fungal
(Najma et al., 2010) and anti-inflammatory (Hynes and
Leftheri, 2005) activity. So far several pyridone derivatives
have advanced into clinical trials or preclinical trials to combat
cancers (Fig. 1). For instance, compound B (BMS-777607)
(Weiqiang et al., 2015) demonstrates selective inhibition of
proliferation in solid tumors by adopting an extended confor-
mation binding to its protein counterpart. Compound C (Liet al., 2015) and D (Rongshi et al., 2006) exhibited potent cyto-
toxicity in vitro against human colon cancer cells HCT-116 and
A549, respectively. Moreover, accumulating evidence indicates
that PFD acts as a multi-targeted inhibitor of TGF-b
(Burghardt et al., 2007), EGFR (Krishnan et al., 2007),
TNF-a (Grattendick et al., 2008), and PFDGF (Levy et al.,
2008). Thereinto, TGF-b and EGFR are also well-validated
targets for anti-cancer agents. Subsequently, we proposed to
develop analogues of pyridone as anti-cancer drugs with the
maintenance of anti-fibrotic effect. As such, investigations in
our group were aimed at designing new synthetic anti-lung
cancer molecules along with anti-fibrotic activity prior to the
present search. Recently, Zhu et al.’ (Weixing et al., 2013) sys-
tematic studies led to the identification of compound 22
(Fig. 1), which displayed both potency and selectivity
(IC50 = 130 lM) toward the A549 cell lines. Importantly, it
is discovered that the existence of aromatic ring on C-5 posi-
tion of pyridin-2(1H)-one scaffold may lead to improvements
in the sensitivity of most compounds toward lung cancer cell
line. However, the activity of compound 22 is relatively weak,
which inspired us to make further modification of pyridone
moiety in the direction of developing novel potent molecules
with equal or greater specificity for lung cancer than com-
pound 22.
For discovering more versatile substituted anti-lung cancer
agents with the maintenance of anti-fibrotic effect, herein we
disclosed design (Scheme 1) and synthesis of 28 novel 1,5-
disubstituted-pyridone derivatives. With the pyridone moiety
fixed, we introduced benzyl group instead of phenyl group at
the N-1 position and different substituents on two aromatic
rings for further optimization, based on the structure of com-
pound 22. The antiproliferative profiles of the synthesized
compounds were evaluated in vitro against human A549 and
mice NIH3T3 cell lines by MTT assays. Additionally, 3D-
QSAR studies were also carried out in the present work to
define the structural determinants required to anti-lung cancer
activity by means of MOE 2014 (Molecular Operating
Environment 2014, Inc., Canada), which accounts for effect
of the structural variability on the pharmacological properties
and prospectively makes for the future design of novel poten-
tial anti-lung cancer drug candidates.2. Results and discussion
2.1. Chemistry
The preparative route used to access the foregoing 1,5-
disubstituted-2(1H)-pyridone analogues is illustrated in
Scheme 2. In detail, twenty-eight compounds were synthesized
starting from 5-methylpyridin-2(1H)-one. To a solution of
starting material in anhydrous 1,4-dioxane, substituted benzyl
bromide, potassium carbonate (K2CO3) and a catalytic
amount of tetrabutylammonium iodide (TBAI) were added
to produce compounds 1a–d in 70–89% yields (Marina et al.,
2015). Alternatively, the reaction also proceeded at room tem-
perature with N,N-dimethylformamide (DMF) as a solvent
and using NaH or Cs2CO3 as base (Suresh and Tipparaju,
2008), though under such conditions the products are not
easily separable from the solvent compared with the former.
In the synthesis, the bromination reaction for intermediates
1a–d was the major challenge that we faced, while this
NO
F
H
N N
O
OO
Cl
H2N
N
O
O
O
O
N
NN
Cl
N
O
HN
H3CO
H3CO
OCH3
OCH3
F
A B
C
N
H3C
O
R
R=H Pirfenidone
R=F AKF-PD
D
N O
HN
N
F3C
O
NHCOCH3
5b
22
Figure 1 Chemical structures of substituted-2(1H)-pyridone derivatives as potent anti-cancer or anti-fibrosis agents.
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(Comins and Lyle, 1976; Morrow and Rapoport, 1974).
Other than to afford the desired compounds 2a–d, it is
observed that the radical reaction also easily led to dibromina-
tion of methyl and bromination of C-3 position of pyridone as
well during the process of exploration. In order to avoid the
occurrence of side reaction as far as possible, compounds
1a–d were treated with N-bromosuccinimide (NBS) to give
common intermediates 2a–d for both series by means of using
2,20-azobis(2-methylpropionitrile) (AIBN) as catalyst, accord-
ing to previously reported methods (Weixing et al., 2013).
Due to instability of bromination products during isolation,
the corresponding crude products 2a–d were directly used for
the following step instead of further purification.
Subsequently, compounds 2a–d obtained from the above reac-
tion and substituted aniline or sodium salt of substituted phe-
nol were dissolved in acetonitrile and stirred at roomtemperature to yield the target compounds 3a–o, 4a–m
(Table 1), respectively. All synthesized compounds gave satis-
factory analytical and spectroscopic data, i.e. 1H NMR, 13C
NMR, and EI-MS, which are in accordance with the assigned
structures.
2.2. Biological activity
All the newly synthesized compounds were investigated for
their cytotoxic activities against two cell lines, human lung ade-
nocarcinoma A549 cells and mouse embryonic fibroblast
NIH3T3 cells, by MTT (3-[4,5-dimethyl-2-thiazolyl]-2,5-diphe
nyl-2H-tetrazolium bromide) assay in vitro, using Cisplatin
(DDP) and PFD as reference compounds. The results
expressed as inhibition constant (IC50) values are summarized
in Table 2, which embodies the difference of activity among
the compounds. The evidence of growth inhibition across
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Scheme 2 General synthesis of compounds 3a–o and 4a–m. Reagents and conditions: (i) K2CO3, TBAI, 1,4-dioxane, Reflux, 20 h, 70–
89%; (ii) NBS, AIBN, CCl4, hv, 100 W, 2 h; (iii) acetonitrile, rt, 3 h, 25–57%; (iv) acetonitrile, rt, 3 h, 27–87%.
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pyridone moiety inhibit cellular proliferation to some extent
and the results revealed several interesting points including
the broad range of potencies in the two series.
2.2.1. Anti-lung cancer activity
Taking compound 22 as the lead, we have carried out struc-
tural modification around the 2(1H)-pyridone series by focus-
ing on the three diversification points at R1, R2, and the
hydrogen bond donor on C-5 position attached to a phenyl
ring. In order to get insight into the effect of different linkers
between pyridone and aryl moiety on antiproliferative activity
among compounds 3a–o and 4a–m, we first introduced
electron-donating group at R1, such as methyl, methoxy
group. On the basis of the data in Table 2, compound 3f with
NH-phenyl linker displayed stronger activity than compound
4g with O-phenyl linker when the substitution is methyl group
at R1 and the other parts are kept constant, whereas, the inhi-
bitory activity of derivatives containing NH-phenyl linker such
as compounds 3j and 3l showed lower activities than that of
those containing O-phenyl linker such as 4h and 4j, regardless
of whether it is monosubstituted or disubstituted by methoxy
group at R1. In addition, it is observed that when substituted
by strong electron-withdrawing group at R1, compounds bear-
ing NH-phenyl linker such as compound 3i dramatically
increased the anti-lung cancer activity compared with those
bearing O-phenyl linker such as 4k. Analysis of substituent
groups in the aromatic ring of the N-1 position indicated that
without methoxy group at R2, the activity of compound with
O-phenyl linker (4g) is inferior to that of compound with
NH-phenyl linker (3f). However, once introduced methoxy
group at R2, the activity of compounds with O-phenyl linker
(4m) is superior to that of compounds with NH-phenyl linker
(3o), which is just the opposite of the phenomenon found inderivatives without methoxy substitution at R2. These results
above suggested that the divergence of substitution at R1 or
R2 may account for the discrepancy of activity of compounds
with different linker and they can serve as important active
groups.
In the case of constant NH-phenyl linker, changing posi-
tion of substituents or varying number of substituents at R1
on phenyl ring could also affect the activities of compounds.
As depicted in Table 2, compound 3a (IC50 = 185 lM) with
one fluorine atom on the 2-position of benzene ring
showed weaker inhibitory activity than compound 3b
(IC50 = 148 lM) with one fluorine atom on the 4-position of
benzene ring. Besides, we found para-chloro derivative 3d to
show a slight improvement in IC50 against A549 as compared
to meta-chloro derivative 3c. Taken together, the activities of
compounds with para position substituted on phenyl ring
increased while those of compounds with ortho or meta posi-
tion substituted brought reduced activity. Interestingly, com-
pounds 3h and 3l (two methyl group at 3,4-position in
benzene ring respectively) gave rise to a noteworthy loss in
activity compared to the analogues bearing only one sub-
stituent (3f, 3k). Nevertheless, compound 3g with two methyl
groups at 2,4-position displayed more potent inhibition than
compound 3f. Compared to compounds 3d and 3e with two
chlorine atoms at 3,4-position on phenyl ring did not exhibit
big changes in activity, but the activity of 3e is even higher
than 3c with only one chlorine atom. Additionally, when the
linker is O-phenyl linker, compounds 4d and 4e containing
two chlorine atoms at R1 had stronger inhibitory activity than
4c owning one chlorine atom substitution. From the analysis
of test results, all the compounds with N-benzyl motif substi-
tuted were more active than those without substituents, sug-
gesting that the presence of substituted N-benzyl moiety
could improve anti-lung cancer activities to a certain extent.
Table 1 Structures of compounds 3a–o and 4a–m.
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Compounds R1 R2 Compounds R1 R2
3a 2-Fluoro H 4a H H
3b 4-Fluoro H 4b 2-Fluoro H
3c 3-Chloro H 4c 2-Chloro H
3d 4-Chloro H 4d 2,4-Dichloro H
3e 2,4-Dichloro H 4e 3,4-Dichloro H
3f 4-Methyl H 4f 2-Methyl H
3g 2,4-Dimethyl H 4g 4-Methyl H
3h 3,4-Dimethyl H 4h 2-Methoxy H
3i 3-Trifluoromethyl H 4i 4-Methoxy H
3j 2-Methoxy H 4j 3,4-Dimethoxy H
3k 3-Methoxy H 4k 3-Trifluoromethyl H
3l 3,4-Dimethoxy H 4l 4-Fluoro 4-Methoxy
3m 4-Methyl 2-Fluoro 4m 4-Methyl 4-Methoxy
3n 4-Methyl 4-Fluoro – – –
3o 4-Methyl 4-Methoxy – – –
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Fibrosis is common in the establishment of benign tumors and
cancers. Evidence has been provided that a close correlation of
fibrosis of various tissues and their potential oncological trans-
formation exists. Certain tissues, which undergo fibrosis, are
subsequently susceptible to carcinogenicity and when tissue
fibrosis in these precancerous tissues is halted, formation of
cancer would be blocked (Kenneth et al., 2006). Taking this
discovery into consideration, the anti-fibrotic activities of the
synthetic derivatives in vitro are also assayed and the IC50
determined, with the purpose of obtaining some agents pos-
sessing anti-lung cancer property and at the same time having
good inhibition of fibrosis.
Just as can been seen from Table 2, most of the novel
derivatives exhibited good inhibitory activities to NIH3T3 cell
lines, among which compound 3a displayed best inhibitory
activity with an IC50 value of 3 lM, far superior to the lead
compound 5b and PFD. Because the activities of compounds
3b, 3d, and 3f wore off gradually, it can be concluded that
fluoro-substitution at para position was favorable to chloro-
substitution and chloro-substitution was better than methyl-
substitution. Additionally, what is most notable is that when
the 3-position of phenyl ring was replaced by methoxy group
(3k), chlorine (3c) and trifluoromethyl (3i) group respectively,
the corresponding activities increased markedly, which indi-
cated that strong electron-withdrawing group contributes to
the improvement of activity against NIH3T3 cell lines most,followed by weaker electron-withdrawing group and then the
electron-donating group. One reason might be that com-
pounds bearing the lipophilic trifluoromethyl or chloro group
could penetrate the cell membrane more easily. And the other
could be that the trifluoromethyl group, a donor of hydrogen
bond, could enhance the binding with target. Moreover,
whether the hydrogen bond donor on C-5 position is NH
group or oxygen group, compounds with dimethoxy-
substitution at R1 showed more potent activity than com-
pounds with mono-substitution. In addition, when the phenyl
ring was substituted by two chlorine or methoxy group, deriva-
tives 3e and 3l, which own NH group, had better inhibitory
activity than derivatives 4d and 4j with oxygen group. While
the para-substitution at R1 and R2 is methyl group and meth-
oxy group separately, compound 3o had higher anti-fibrotic
ability with an IC50 value of 22 lM than compound 4m with
an IC50 value of 40 lM.
In summary, in order to have a good knowledge about the
effect of the variations at R1, R2, and the hydrogen bond
donor on antiproliferative activity, we made comprehensive
assessments of the biological results. It is indicated that some
of the tested compounds showed excellent inhibitory activity
against A549 cell lines than the lead compound 5b. Besides,
all of the tested compounds are far more excellent compared
with PFD and even better than the lead compound 5b in
anti-fibrotic activity. In accordance with the purpose of initial
design, some compounds possessed both good anti-lung cancer
Table 2 In vitro antiproliferative activity (IC50, lM) against A549 and NIH3T3 for compounds 3a–o, and 4a–m.
Compounds IC50 ± SD (lM)
a NIAd Compounds IC50 ± SD (lM)
a NIAd
A549 NIH3T3 A549 NIH3T3
3a 185.00 ± 6.32 3.00 ± 0.12 0.016 4a 251.00 ± 9.01 59.00 ± 1.21 0.235
3b 148.0 ± 8.13 12.00 ± 0.34 0.081 4b 403.00 ± 8.45 62.00 ± 2.03 0.154
3c 103.0 ± 2.92 13.00 ± 0.63 0.126 4c 255.00 ± 9.43 11.00 ± 0.65 0.043
3d 80.00 ± 3.43 17.00 ± 0.48 0.213 4d 38.00 ± 2.17 18.00 ± 0.22 0.474
3e 86.00 ± 3.12 14.00 ± 0.79 0.163 4e 235.00 ± 3.95 45.00 ± 1.36 0.191
3f 153.00 ± 9.25 61.00 ± 3.63 0.399 4f 497.00 ± 15.93 39.00 ± 1.58 0.078
3g 119.00 ± 4.51 28.00 ± 1.58 0.235 4g 345.00 ± 7.98 41.00 ± 2.93 0.119
3h 424.00 ± 24.22 22.00 ± 0.92 0.052 4h 9.00 ± 0.94 49.00 ± 2.37 1.256
3i 40.00 ± 1.36 9.00 ± 0.24 0.225 4i 197.00 ± 6.32 30.00 ± 1.74 0.152
3j 265.00 ± 9.52 135.0 0 ± 4.95 0.509 4j 506.00 ± 20.81 27.00 ± 1.16 0.053
3k 219.0 ± 8.47 162.0 ± 3.12 0.740 4k 145.00 ± 5.67 20.00 ± 0.92 0.138
3l 568.0 ± 26.74 14.0 ± 0.57 0.025 4l 20.00 ± 0.75 55.00 ± 2.75 2.750
3m 163.00 ± 5.63 11.0 ± 0.23 0.067 4m 44.00 ± 1.26 40.00 ± 1.97 0.909
3n 89.00 ± 2.54 51.0 ± 1.79 0.573 DDPb 10.00 ± 0.29 3.00 ± 0.22 0.300
3o 81.00 ± 4.28 22.0 ± 1.16 0.272 PFDc – 454.00 ± 10.45 –
22 130.00 ± 6.16 – – 5b – 80.00 ± 2.89 –
a Antiproliferative activity was measured using the MTT assay. IC50 values are the average of three independent experiments run in triplicate.
Variation was generally 5%.
b,c Used as positive controls. DDP stands for Cisplatin, and PFD for Pirfenidone.
d NIA= IC50 (NIH3T3)/IC50 (A549).
Table 4 Experimental, predicted inhibitory activity of all
synthesized compounds against NIH3T3 by 3D-QSAR models.
Compounds Experimental
pIC50
a
Predicted
pIC50
Residual
error
3a 5.523 5.4342 0.0888
3b 4.921 4.8381 0.0829
3c 4.886 4.8295 0.0565
3d 4.770 4.8908 0.1208
3e 4.854 4.9199 0.0659
3f 4.215 4.2867 0.0717
3g 4.553 4.5357 0.0173
3h 4.658 4.5263 0.0764
3i 5.046 4.9250 0.1210
3j 3.870 3.8535 0.0165
3k 3.790 3.8656 0.0756
3l 4.854 4.8886 0.0565
3m 4.959 5.0951 0.0864
3n 4.292 4.3479 0.0559
3o 4.658 4.5263 0.1317
4a 4.229 4.3565 0.1275
4b 4.208 4.1297 0.0783
4c 4.959 4.8726 0.0864
4d 4.745 4.7990 0.0540
4e 4.347 4.3477 0.0007
4f 4.409 4.2815 0.1275
4g 4.387 4.3248 0.0622
4h 4.310 4.3515 0.0415
4i 4.523 4.5767 0.0537
4j 4.569 4.5487 0.0203
4k 4.699 4.7543 0.0553
4l 4.260 4.2543 0.0057
4m 4.398 4.3233 0.0747
a The IC50 values of the compounds against NIH3T3 (Table 2)
were converted into pIC50 values by using the online calculator
(http://www.sanjeevslab.org/tools-IC50.htmL).
Table 3 Experimental, predicted inhibitory activity of all
synthesized compounds against A549 by 3D-QSAR models.
Compounds Experimental
pIC50
a
Predicted
pIC50
Residual
error
3a 3.7330 3.6265 0.1065
3b 3.8300 3.9338 0.1038
3c 3.9870 3.8816 0.1054
3d 4.0970 4.1054 0.0084
3e 4.0660 4.1960 0.1300
3f 3.8150 3.7499 0.0651
3g 3.9240 3.9213 0.0027
3h 3.3730 3.4965 0.1235
3i 4.3800 4.4108 0.0308
3j 3.5770 3.5544 0.0226
3k 3.6600 3.5810 0.0790
3l 3.2460 3.2097 0.0363
3m 3.7880 3.8510 0.0630
3n 4.0510 3.9516 0.0994
3o 4.0920 4.2051 0.1131
4a 3.6000 3.4790 0.1210
4b 3.3950 3.5337 0.1387
4c 3.5930 3.6910 0.0980
4d 4.4200 4.2049 0.2151
4e 3.6290 3.6694 0.0404
4f 3.3040 3.4602 0.1562
4g 3.4620 3.4314 0.0306
4h 4.4090 4.4552 0.0462
4i 3.7060 3.7479 0.0419
4j 3.2960 3.2139 0.0821
4k 3.8390 3.8432 0.0042
4l 4.6990 4.6665 0.0325
4m 4.3570 4.2572 0.0998
a The IC50 values of the compounds against A549 (Table 2) were
converted into pIC50 values by using the online calculator (http://
www.sanjeevslab.org/tools-IC50.htmL).
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4d, 4h, and 4l. After comparing the selectivity of 1,5-
disubstituted-2(1H)-pyridone derivatives, we discovered that
of all the derivatives, compound 4l displayed the best potency
(IC50 = 20 lM) and selectivity (NIA = 2.750) toward the
A549 cell line as well as showing good anti-fibrotic activity
(IC50 = 55 lM).
2.3. 3D-QSAR
For the sake of further acquiring a systematic structure and
activity relationships (SAR) profile of the synthesized com-
pounds and exploring a more powerful and selective anti-
lung cancer agent, twenty-eight compounds with definite
IC50 values against A549 and NIH3T3 cell lines were selected
as the model dataset by means of the MOE 2014 software. By
convention, the pIC50 scale (logIC50), in which higher values
indicated exponentially greater potency, was used as a method
to measure inhibitory activity. Therefore, 3D-QSAR modelsA 
y=0.939x+0.2
B 
y=0.954x+0.21
Figure 2 Correlation plot of experimental versus predicted biologica
model.were constructed on the pharmacophore-based molecular
alignment to reasonably evaluate the designed molecules by
using the corresponding pIC50 values which were converted
from the obtained IC50 values. The way of this transformation
was derived from an online calculator developed from an
Indian medicinal chemistry laboratory (http://www.sanjeevs-
lab.org/tools-IC50.htmL). The AutoGPA-based 3D-QSAR
models obtained in the present study gave the observed and
predicted pIC50 (lM) values along with their corresponding
residual values against A549 and NIH3T3, which are pre-
sented in Tables 3 and 4, respectively. For a further step, mod-
els with good predictive ability were generated with the cross-
validation correlation coefficient q2 values for A549 and
NIH3T3 being 0.597 and 0.649. Statistically, the squared cor-
relation coefficient R2 values were found to be 0.939 and 0.954.
It apparently emerges the quite good agreement between pre-
dicted and observed pIC50 values, further highlighting the
robustness of the present 3D-QSAR model. Their graphical
relationships between predicted and experimental pIC50 values334, R2=0.939 
23, R2=0.954 
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728 Q. Xu et al.for both A549 and NIH3T3 are illustrated in Fig. 2. Notably,
the activities of the prospectively tested compounds turned out
to be in line with the predictions. As depicted in the figures, the
models not only help to demonstrate the reliability of activity
for new 1,5-disubstituted-2(1H)-pyridone derivatives as anti-
lung cancer agents but also serve as a useful guide for the
design of new inhibitors with better activities.
Simultaneously, the molecules aligned with the iso-surfaces
of the 3D-QSAR model coefficients on van der Waals grids
and electrostatic potential grids are listed in Fig. 3. It needs
to point out that negative charge is favoured near red contours
and blue contours represent regions of desirable positive
charge. Similarly, steric map indicated areas where steric bulk
is predicted to increase (green) or decrease (yellow) activity
(Dandan et al., 2013). It is widely acceptable that a better inhi-
bitor based on the 3D-QSAR model should have strong Van
der Waals attraction in the green areas and a polar group in
the blue electrostatic potential areas.
According to the maps (Fig. 3A), compounds with a high
negative charge at para position on aromatic ring would
possess higher activity, validating that methoxy group at
para position on the aromatic ring is a better choice than
methyl substitution and CH3 is worse than H, such as com-
pounds 4i (IC50 = 197 lM), 4a (IC50 = 251 lM), and 4g
(IC50 = 345 lM). It is also worthy to note that steric bulk is
disfavored at the ortho- or meta-position in the aromatic ringFigure 3 3D-QSAR model coefficients on electrostatic potential grids
contours represent negative electrostatic coefficients while blue contou
indicate high steric tolerance, whereas yellow contours indicate denote
ligand.(yellow contour), which complies with the biological results
that compounds with methyl group at the ortho-position of
N-1 benzyl ring showed lower levels of antiproliferative
activity than compounds only with hydrogen at the same
position, e.g. 4f (IC50 = 497 lM) and 4a (IC50 = 251 lM).
In contrast, the use of bulkier and electronegative group at
the para-position of N-1 benzyl ring appeared to be reasonably
well tolerated. For instance, compound 4m (R1 = 4-CH3,
R2 = 4-OCH3) and compound 3n (R1 = 4-CH3, R2 = 4-F)
gave IC50 values of 44 lM and 89 lM, respectively, better than
those of their counterpart compound 4g (IC50 = 345 lM) and
compound 3f (IC50 = 153 lM). As a result, data summarized
above demonstrated that compounds 4l, the most potent
inhibitor (IC50 = 20 lM) with suitable substituent possessed
an outstanding activity, whose 3D-QSAR model is presently
developed as Fig. 3C. Aside from the above discussion, struc-
tural interpretation of the 3D-QSAR based on the inhibitory
activity against NIH3T3 (Fig. 3B) also suggests there appear
to be two major variations contributing to the differences of
anti-fibrotic activity: (i) Electronegative substitution is favored
at the meta-position of aromatic ring (red contour); (ii) steric
bulk in the para-position of N-1 benzyl ring is disfavored (yel-
low contour). Evidently, meta-trifluoromethyl compound 3i
(R1 = 3-CF3, R2 = H) showed the highest inhibitory ability
among the compounds containing electronegative substitution
at this position, with the order of anti-fibrotic activity beingand van der Waals grids for A549 (A, C) and NIH3T3 (B, D). Red
rs represent positive electrostatic coefficients. The green contours
regions of unfavorable steric effects at particular region around the
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molecule is shown in Fig. 3 D, confirming that compound 3a
with small stereospecific blockade at R2 and electronegative
at R1 has strongest inhibitory effect on NIH3T3 cells.
Fig. 4 indicates the best hypothesis with pharmacophoric
features shared by all compounds in the dataset. F1 hydropho-
bic feature in Fig. 4A suggests the critical role in the anti-lung
cancer profiles for F1 occupation, further validating the con-
clusion reported previously that F1 occupation can improve
the sensitivity of most compounds to lung cancer cell line,
whereas an aromatic (Aro/PiR) p-ring center contoured by
orange contour in Fig. 4B illustrated that the benzene ring at
N-1 benzyl group plays an important role in anti-fibrotic
activity.
According to the results, the promising 3D-QSAR models
fitted the inhibitory activity well thus provided us cogent foun-
dation and new ideas about designing and optimizing more
effective derivatives against anti-lung cancer agents, which
paves the way for us in the further study. Besides, the commonFigure 4 The 3D-QSAR pharmacophore model based aligned
compounds for A549 (A) and NIH3T3 (B).pharmacophore features further helped in screening out the
potential ligand for anti-lung cancer activity.
3. Conclusions
In our present work, two series of 1,5-disubstituted-2(1H)-
pyridone analogues were synthesized and evaluated for their
biological activities. Preliminary results revealed that these
compounds exhibited tolerated antiproliferative activities
against A549 cells and NIH3T3 cells with micromolar poten-
cies. Based on the preliminary results, compounds 3i, 4d, 4h,
4l and 4m displayed comparable or superior antiproliferative
activities to those of the lead active compound 22. Most strik-
ingly, compound 4l demonstrated the most selective activity
which suppressed the growth of A549 cells with an IC50 value
of 20 lM, comparable with the positive control DDP, and
exhibited good inhibitory activity against fibroblasts with an
IC50 of 55 lM. Importantly, the anti-fibrotic activities of the
synthetic compound universally advantage over that of PFD,
and out of the tested compounds, compound 3a possessed best
anti-fibrotic activity with an IC50 value of 3 lM, 151 times as
much as that of PFD. Simultaneously, QSAR models were
also built with the activity data to check the previous work
as well as to provide a reliable tool for design of anti-lung
cancer agents in future. Therefore, it can be concluded that
1,5-disubstituted-2(1H)-pyridone derivatives are promising
leads for further study as potential anti-lung cancer agents.
The results of this study provided valuably theoretical basis
for development of more potential therapeutic drugs possess-
ing stronger anti-lung cancer activities with the maintenance
of anti-fibrotic property to fight against lung cancer.
4. Experimental protocols
4.1. Materials and measurements
Unless otherwise indicated, all reagents and solvents used in
current study were of analytical grade and were used as
obtained from commercial suppliers without further purifica-
tion. All reactions were monitored by Thin layer chromatogra-
phy (TLC) on 0.25 mm glass-backed silica gel plates (silica
GF-254), and visualized with ultraviolet (UV) light (254 nm).
Column chromatography was carried out using glass columns
with silica gel (200–300 mesh, Aldrich Chemical). All of the
final compounds have purity greater than 95%, which were
determined by analytical reverse-phase liquid chromatogram
(Instrument model: Shimadzu LC-2010). A Welchrom C18
(4.6 mm  250 mm, 5 lm) was used at a temperature of 40 
C. The mobile phase consisted of methanol (60–85%) and
water (40–15%). Analysis was conducted over 8.0 min run
time at a flow rate of 1.0 mL/min. The Melting points were
determined on a XT4MP apparatus (Taike Corp., Beijing,
China) and are uncorrected. 1H NMR spectra and 13C NMR
were recorded on either Varian INOV-400FT or INOV-
500FT spectrophotometer operating at the indicated frequen-
cies in DMSO-d6. Chemical shifts are expressed in parts per
million (ppm) relative to an internal standard: tetramethylsi-
lane (ppm = 0.00). Coupling constants are reported in units
of hertz (Hz). Peak multiplicity abbreviations are as follows:
s (singlet), d (doublet), dd (doublet of doublets), t (triplet),
and m (multiplet).
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4.2.1. General procedure for synthesis of 1-substituted benzyl-5-
methylpyridin-2(1H)-one (1a–d)
A mixture of 5-methylpyridin-2(1H)-one (0.10 mol), substi-
tuted bromomethyl-benzene (0.12 mol), potassium carbonate
(0.16 mol), TBAI (0.001 mol) was dissolved in 1,4-dioxane
and then stirred under reflux condition for 10 h. After the solu-
tion was cooled to the room temperature, the formed precipi-
tate was filtered and washed with 40 mL 1,4-dioxane. The filter
liquor was concentrated in vacuo and then the residue was
purified by column chromatography (petroleum ether/ethyl
acetate = 2:1). Fractions containing product were concen-
trated in vacuo to afford 1a–d in 70–89% yields.
4.2.1.1. 1-Benzyl-5-methylpyridin-2(1H)-one (1a). Yellow
solid, yield: 75%. M.p.: 66.7–67.5 C. 1H NMR (400 MHz,
DMSO-d6): d 7.69 (s, J= 1.6 Hz, 1H, CH‚), 7.35–7.42 (d,
J= 9.2 Hz, 1H, CH‚), 7.17–7.20 (m, J= 4.8 Hz, 2H,
ArAH), 7.06–7.10 (m, 1H, ArAH), 6.84–6.86 (m,
J= 8.0 Hz, 2H, ArAH), 6.39–6.42 (d, J= 9.2 Hz, 1H,
CH‚), 5.06 (s, 2H, ACH2A), 2.03 (s, 3H, ACH3).
13C
NMR (100 MHz, DMSO-d6): d 160.21 (C‚O), 142.95
(C‚C), 136.54 (Aromatic carbon), 129.78 (C‚C), 128.45
(2  Aromatic carbon), 127.69 (Aromatic carbon), 126.87
(2  Aromatic carbon), 121.20 (C‚C), 116.84 (C‚C), 48.51
(ACH2A), 17.84 (ACH3). MS Calcd. for C13H13NO: 199.1.
EI-MS m/z: 199.1 [M]+.
4.2.1.2. 1-(2-Fluorobenzyl)-5-methylpyridin-2(1H)-one (1b).
White solid, yield: 70%. M.p.: 89.6–90.4 C. 1H NMR
(400 MHz, DMSO-d6): d 7.74 (s, 1H, CH‚), 7.42–7.44 (d,
J= 9.2 Hz, 1H, CH‚), 7.31–7.34 (m, 1H, ArAH), 7.24–7.28
(m, 1H, ArAH), 7.06–7.12 (m, 2H, ArAH), 6.39–6.42 (d,
J= 9.2 Hz, 1H, CH‚), 5.02 (s, 2H, ACH2A), 2.05 (s, 3H,
ACH3).
13C NMR (100 MHz, DMSO-d6): d 161.45 (C‚O),
159.40, 156.38, 141.83(C‚C), 137.24, 128.73 (C‚C), 127.64,
126.95, 123.16, 120.13 (C‚C), 117.52 (C‚C), 115.28, 43.67
(ACH2A), 17.79 (ACH3). MS Calcd. for C13H12FNO: 217.1.
EI-MS m/z: 217.1 [M]+.
4.2.1.3. 1-(4-Methoxybenzyl)-5-methylpyridin-2(1H)-one
(1c). White solid, yield: 89%. M.p.: 85.7–67.6 C. 1H NMR
(400 MHz, DMSO-d6): d 7.75 (s, 1H, CH‚), 7.39–7.42 (d,
J= 9.2 Hz, 1H, CH‚), 7.22–7.24 (m, J= 8.4 Hz, 2H,
ArAH), 6.84–6.87 (m, 4H, ArAH), 6.36–6.39 (m,
J= 9.2 Hz, 1H, CH‚), 4.98 (s, 2H, ACH2A), 3.76 (s, 3H,
AOCH3), 2.08 (s, 3H, ACH3).
13C NMR (100 MHz, DMSO-
d6): d 161.23 (C2), 158.94, 140.76 (C‚C), 136.93, 129.75
(2  Aromatic carbon), 124.69 (C‚C), 119.94 (C‚C),
117.28 (C‚C), 114.13 (2  Aromatic carbon), 50.69
(AOCH3), 43.62 (ACH2), 17.87 (ACH3). MS Calcd. for
C14H15NO2: 229.1. EI-MS m/z: 229.1 [M]
+.
4.2.1.4. 1-(4-Fluorobenzyl)-5-methylpyridin-2(1H)-one (1d).
White crystal, yield: 84%. M.p.: 82.6–83.7 C. 1H NMR
(400 MHz, DMSO-d6): d 7.72 (s, 1H, CH‚), 7.41–7.44 (d,
J= 9.6Hz, 1H, CH‚), 7.32–7.35 (m, 2H, ArAH), 7.10–7.14
(m, J= 8.4 Hz, 2H, ArAH), 6.37–6.41 (m, J= 9.2 Hz, 1H,
CH‚), 5.03 (s, 2H, ACH2A), 2.05 (s, 3H, ACH3).
13C
NMR (100 MHz, DMSO-d6): d 161.65 (C‚O), 160.91,158.43, 141.35 (C‚C), 137.26, 129.75 (2  Aromatic carbon),
125.07 (C‚C), 120.16 (C‚C), 117.89 (C‚C), 115.36
(2  Aromatic carbon), 43.72 (ACH2A), 17.63 (ACH3). MS
Calcd. for C13H12FNO: 217.1. EI-M S m/z: 217.1 [M]
+.
4.2.2. General procedure for synthesis of 1-substituted benzyl-5-
(bromomethyl) pyridin-2(1H)-one (2a–d)
To a solution of 1a–d (5.0 mmol) in 75.0 mL carbon tetrachlo-
ride (CCl4) was added 0.4 mmol azodiisobutyronitrile (AIBN)
followed by 5.0 mmol N-bromosuccinimide (NBS). The mix-
ture was heated at reflux under the irradiation of 100 W light
(Brand name: High Bay Light; Model: HL14600) for 2 h.
After completion of the reaction, the solution was cooled to
the room temperature and then the resulting solid was filtered.
The filtrate solvent was evaporated under reduced pressure to
obtain crude 1-substituted benzyl-5-(bromomethyl) pyridine-2
(1H)-one (2a–d). Given the instability during isolation process,
the crude product 2a–d was directly applied to the next step
without further purification.
4.2.3. General procedure for synthesis of 1-substituted benzyl-5-
substituted ((phenylamino)methyl)pyridin-2(1H)-one (3a–o)
To the above obtained crude product 2a–d (4.0 mmol) in
100 mL round-bottom flask, 35.0 mL acetonitrile and substi-
tuted aniline (4.0 mmol) were added. The reaction solution
was allowed to stir at room temperature for 3 h, and moni-
tored by TLC. After the reaction was completed, the precipi-
tate was filtered off and washed with 5.0 mL of acetonitrile.
The combined organic layers were then concentrated in vacuo.
The residue was subjected to silica gel chromatography using
30% ethyl acetate in petroleum ether to afford the compounds
3a–o. The overall yields were 25–57% calculated with 2a–d as
the initial materials.
4.2.4. General procedure for synthesis of 1-substituted benzyl-5-
substituted (phenoxymethyl)pyridin-2(1H)-one (4a–m)
To a solution of sodiumhydroxide (0.102 mol) in 20.0 mL anhy-
drous ethanol was added a phenol derivative (0.1 mol), and then
the mixture was stirred for 0.5 h at 60 C. The reaction solution
was removed under reduced pressure after it cooled down.
Upon concentration, the resulting mixture was dried in vacuum
at 40 C for 1 h to furnish sodium phenolate (0.1 mol).
Subsequently, to a stirred solution of the crude 1-substituted
benzyl-5-(bromomethyl)pyridin-2(1H)-one (2a–d) (0.10 mol)
in 35.0 mL acetonitrile, sodium phenolate (0.1 mol) was added
and the stirring was maintained at room temperature for 3 h
(monitored by TLC). Filtrations and column chromatography
(50% ethyl acetate in petroleum ether) were performed to
provide the desired compounds (4a–m). The overall yields were
27–87% calculated with 2a–d as the initial materials.
4.3. Spectral properties of 1,5-disubstituted-2(1H)-pyridone
derivatives
4.3.1. 1-Benzyl-5-(((2-fluorophenyl)amino)methyl)pyridin-2
(1H)-one (3a)
Light yellow oil, yield: 39%. 1H NMR (400 MHz, DMSO-d6) :
d 7.83–7.84 (s, J= 1.6 Hz, 1H, CH‚), 7.48–7.51 (m,
J= 9.2 Hz, 1H, CH‚), 7.23–7.35 (m, 6H, ArAH), 6.97–7.02
(t, J= 7.6 Hz, 1H, ArAH), 6.83–6.90 (m, J= 7.2 Hz, 1H,
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1H, CH‚), 6.40–6.42 (t, J= 5.2 Hz, 1H, ANHA), 5.06 (s,
2H, ACH2A), 4.05–4.06 (d, J= 6.0 Hz, 2H, ACH2A).
13C
NMR (100 MHz, DMSO-d6) : d 166.26 (C2), 154.92 (C40),
157.43 (C40), 145.77 (C4), 142.45 (C200), 142.16 (C30), 133.67
(C6), 132.71 (C400, 600), 132.65 (C300, 700), 129.74 (C500), 125.01
(C70), 121.91 (C5), 121.04 (C60), 119.61 (C3), 119.43 (C40),
117.69 (C80), 56.34 (C10), 47.51 (C100). MS Calcd. for
C19H17FN2O: 308.1. EI-MS m/z: 308.2 [M]
+.
4.3.2. 1-Benzyl-5-(((4-fluorophenyl)amino)methyl)pyridin-2
(1H)-one (3b)
White powder, yield: 41%. M.p.: 105.3–106.2 C. 1H NMR
(400 MHz, DMSO-d6): d 7.79 (s, 1H, CH‚), 7.43–7.46 (m,
J= 4.2 Hz, 1H, CH‚), 7.24–7.37 (m, 5H, ArAH), 6.87–6.91
(m, J= 4.8 Hz, 2H, ArAH), 6.56–6.59 (m, 2H, ArH), 6.41–
6.43 (d, J= 5.6 Hz, 1H, CH‚), 5.98–6.01 (t, J= 7.0 Hz,
1H, ANHA), 5.06 (s, 2H, ACH2A), 3.93–3.95 (d,
J= 6.4 Hz, 2H, ACH2A).
13C NMR (100 MHz, DMSO-d6):
d 161.31 (C2), 155.89 (C60), 153.59 (C60), 145.26 (C4), 141.03
(C30), 137.72 (C200), 137.29 (C6), 128.79 (C400,600), 127.94 (C300,
700), 127.78 (C500), 120.15 (C5), 116.97 (C3), 115.38 (C40, 80),
113.60 (C50,70), 51.42 (C10), 43.92 (C100). MS Calcd. for
C19H17FN2O: 308.1. EI-MS m/z: 308.2 [M]
+.
4.3.3. 1-Benzyl-5-(((3-chlorophenyl)amino)methyl)pyridin-2
(1H)-one (3c)
White powder, yield: 49%. M.p.: 129.1–130.1 C. 1H NMR
(400 MHz, DMSO-d6): d 7.81 (s, J= 2.0 Hz, 1H, CH‚),
7.41–7.44 (m, J= 9.2 Hz, 1H, CH‚), 7.25–7.33 (m, 5H,
ArAH), 7.02–7.06 (m, J= 8.0 Hz, 1H, ArAH), 6.59–6.60
(m, 1H, ArAH), 6.52–6.55 (m, J= 8.0 Hz, 2H, ArAH), 6.43
(m, 1H, CH‚), 6.38 (m, 1H, ANHA), 5.05 (s, 2H,
ACH2A), 3.97–3.99 (d, J= 5.6 Hz, 2H, ACH2A).
13C NMR
(100 MHz, DMSO-d6): d 151.26 (C2), 140.04 (C30), 130.87
(C4), 127.66 (C200), 127.33 (C70), 123.88 (C6), 120.59 (C5),
118.79 (C400, 600), 117.91 (C300, 700), 117.75 (C500), 110.24 (C60),
106.52 (C3), 105.59 (C50), 101.48 (C40), 99.62 (C80), 41.46
(C10), 33.11 (C100). MS Calcd. for C19H17ClN2O: 324.1. EI-
MS m/z: 324.2 [M]+.
4.3.4. 1-Benzyl-5-(((4-chlorophenyl)amino)methyl)pyridin-2
(1H)-one (3d)
Light yellow powder, yield: 45%. M.p.: 123.9–125.0 C. 1H
NMR (500 MHz, DMSO-d6): d 7.77–7.78 (s, J= 2 Hz, 1H,
CH‚), 7.42–7.44 (m, J= 7.2 Hz, 1H, CH‚), 7.24–7.33 (m,
5H, ArAH), 7.05–7.07 (m, J= 7.2 Hz, 2H, ArAH), 6.58–
6.60 (m, J= 7.2 Hz, 2H, ArAH), 6.41–6.43 (m, J= 7.2 Hz,
1H, CH‚), 6.24–6.25 (m, J= 4.4 Hz, 1H, ANHA), 5.06 (s,
2H, ACH2A), 3.95–3.97 (d, J= 4.8 Hz, 2H, ACH2A).
13C
NMR (125 MHz, DMSO-d6): d 160.94 (C2), 147.13 (C30),
140.61 (C4), 137.36 (C200), 136.99 (C6), 128.47 (C50, 70), 128.45
(C400, 600), 127.60 (C300, 700), 127.43 (C500), 119.85 (C5), 116.32
(C3), 113.84 (C40, 80), 51.08 (C10), 43.06 (C100). MS Calcd. for
C19H17ClN2O: 324.1. EI-MS m/z: 324.1 [M]
+.
4.3.5. 1-Benzyl-5-(((2,4-dichlorophenyl)amino)methyl)pyridin-
2(1H)-one (3e)
Light yellow crystal, yield: 52%. M.p.: 101.9–102.7 C. 1H
NMR (400 MHz, DMSO-d6): d 7.77–7.78 (s, J= 2.0 Hz, 1H,CH‚), 7.45–7.48 (m, J= 9.2 Hz, 1H, CH‚), 7.28–7.35 (m,
4H, ArAH), 7.22–7.24 (m, 2H, ArAH), 7.07–7.10 (m,
J= 8.8 Hz, 1H, ArAH), 6.67–6.69 (m, J= 9.4 Hz, 1H,
ArAH), 6.40–6.42 (m, J= 9.2 Hz, 1H, CH‚), 6.17–6.20 (m,
J= 6.0 Hz, 1H, ANHA), 5.05 (s, 2H, ACH2A), 4.11–4.13
(d, J= 6.0 Hz, 2H, ACH2A).
13C NMR (100 MHz, DMSO-
d6): d 161.78 (C2), 143.05 (C4), 141.03 (C30), 137.73 (C200),
137.50 (C50), 129.11 (C6), 128.86 (C400, 600), 128.17 (C300, 700),
128.14 (C70), 120.54 (C500), 119.97 (C60, C5), 119.19 (C40),
116.87 (C3), 113.45 (C80), 51.81 (C10), 42.99 (C100). MS Calcd.
for C19H16Cl2N2O: 358.1. EI-MS m/z: 358.1 [M]
+.
4.3.6. 1-Benzyl-5-((p-tolylamino)methyl)pyridin-2(1H)-one
(3f)
White crystal, yield: 38%. M.p.: 120.5–121.0 C. 1H NMR
(400 MHz, DMSO-d6): d 7.77–7.78 (s, J= 2.0 Hz, 1H,
CH‚), 7.43–7.46 (m, J= 9.2 Hz, 1H, CH‚), 7.24–7.33 (m,
5H, ArAH), 6.85–6.87 (m, J= 8.4 Hz, 2H, ArAH), 6.49–
6.51 (m, J= 8.4 Hz, 2H, ArAH), 6.39–6.42 (d, J= 9.2 Hz,
1H, CH‚), 5.81–5.84 (m, J= 6.0 Hz, 1H, ANHA), 5.05 (s,
2H, ACH2A), 3.93–3.94 (d, J= 5.6 Hz, 2H, ACH2A), 2.13
(s, 3H, ACH3).
13C NMR (100 MHz, DMSO-d6): d 161.29
(C2), 146.29 (C30), 140.99 (C4), 137.74 (C200), 137.19 (C60),
129.56 (C50,70), 128.78 (C400, 600), 127.92 (C300, 700), 127.75 (C6),
124.72 (C500), 120.06 (C5), 117.29 (C3), 112.99 (C400, 800), 51.42
(C10), 43.67 (C100), 20.40 (ACH3). MS Calcd. for C20H20N2O:
304.2. EI-MS m/z: 304.2 [M]+.4.3.7. 1-Benzyl-5-(((2,4-dimethylphenyl)amino)methyl)
pyridin-2(1H)-one (3g)
White powder, yield: 47%. M.p.: 154.5–156.1 C. 1H NMR
(400 MHz, DMSO-d6) : d 7.75 (s, 1H, CH‚), 7.46–7.49 (m,
J= 9.6 Hz, 1H, CH‚), 7.23–7.33 (m, 5H, ArAH), 6.72–6.77
(m, 2H, ArAH), 6.40–6.41 (m, 1H, ArAH), 6.38–6.39 (m,
1H, CH‚), 5.21 (s, 1H, ANHA), 5.05 (s, 2H, ACH2A),
4.02–4.04 (d, J= 6.0 Hz, 2H, ACH2A), 2.12 (s, 3H, ACH3),
2.06 (s, 3H, ACH3).
13C NMR (100 MHz, DMSO-d6): d
161.62 (C2), 143.76 (C30), 141.06 (C4), 137.78 (C200), 137.24
(C60), 131.12 (C50), 128.96 (C400, 600), 128.05 (C300, 700), 127.23
(C6), 124.91 (C700), 122.67 (C500), 120.15 (C5), 117.90 (C3),
110.63 (C80), 51.67 (C10), 43.55 (C100), 20.49 (ACH3), 18.09
(ACH3). MS Calcd. for C21H22N2O: 318.2. EI-MS m/z:
318.2 [M]+.4.3.8. 1-Benzyl-5-(((3,4-dimethylphenyl)amino)methyl)
pyridin-2(1H)-one (3h)
Light yellow solid, yield: 45%. M.p.: 112.4–114.3 C. 1H NMR
(400 MHz, DMSO-d6): d 7.77 (s, 1H, CH‚), 7.42–7.44 (m,
J= 9.6 Hz, CH‚), 7.24–7.31 (m, 5H, ArAH), 6.78–6.80 (m,
J= 8 Hz, 1H, ArAH), 6.38–6.41 (m, 2H, ArAH), 6.30–6.32
(m, J= 8 Hz, 1H, CH‚), 5.73–5.76 (m, J= 5.6 Hz, 1H,
ANHA), 5.04 (s, 2H, ACH2A), 3.92–3.93 (d, J= 5.6 Hz,
2H), 2.06 (s, 3H, CH3), 2.04 (s, 3H, CH3).
13C NMR
(100 MHz, DMSO-d6): d 161.41 (C2), 146.57 (C30), 141.03
(C4), 137.74 (C200), 137.14 (C50), 136.52 (C70), 130.15 (C6),
128.83 (C400, 600), 127.95 (C300, 700), 127.81 (C500), 123.77 (C60),
120.09 (C5), 117.59 (C3), 114.65 (C40), 110.53 (C80), 51.53
(C10), 43.58 (C100), 20.09 (ACH3), 18.72 (ACH3). MS Calcd.
for C21H22N2O: 318.2. EI-MS m/z: 318.2 [M]
+.
732 Q. Xu et al.4.3.9. 1-Benzyl-5-(((3-(trifluoromethyl)phenyl)amino)methyl)
pyridin-2(1H)-one (3i)
Light yellow powder, yield: 51%. M.p.: 108.5–110.6 C. 1H
NMR (500 MHz, DMSO-d6): d 7.82 (s, 1H, CH‚), 7.44–
7.46 (m, J= 7.1 Hz, 1H, CH‚), 7.24–7.32 (m, 6H, ArAH),
6.82–6.84 (m, J= 7.2 Hz, 3H, ArAH), 6.55–6.57 (m,
J= 4.4 Hz, 1H, ANHA), 6.42–6.44 (m, J= 7.6 Hz, 1H,
CH‚), 5.06 (s, 2H, ACH2A), 4.03–4.04 (d, J= 4.4 Hz, 2H,
ACH2A).
13C NMR (125 MHz, DMSO-d6): d 161.45 (C2),
149.19 (C30), 141.05 (C4), 137.82 (C200), 137.52 (C50), 130.33,
130.25 (C70), 128.94 (C6, 400, 600), 128.04 (C300, 500, 700), 127.92
(ACF3), 120.45 (C5), 116.57 (C3), 116.26 (C80), 112.39 (C60),
108.70 (C40), 51.65 (C10), 43.29 (C100). MS Calcd. for
C20H17F3N2O: 358.1. EI-MS m/z: 358.1 [M]
+.
4.3.10. 1-Benzyl-5-(((2-methoxyphenyl)amino)methyl)pyridin-
2(1H)-one (3j)
Light yellow oil, yield: 57%. 1H NMR (500 MHz, DMSO-d6):
d 7.76 (s, 1H, CH‚), 7.45–7.47 (m, J= 8.8 Hz, 1H, CH‚),
7.23–7.30 (m, 5H, ArAH), 6.77–6.79 (m, J= 7.6 Hz, 1H,
ArAH), 6.68–6.72 (m, J= 7.2 Hz, 1H, ArAH), 6.52–6.56
(m, 2H, ArAH), 6.38–6.40 (m, J= 8.8 Hz, 1H, CH‚), 5.37
(s, 1H, ANHA), 5.05 (s, 2H, ACH2A), 4.03 (d, 2H,
ACH2A), 3.75 (s, 3H, ACH3).
13C NMR (125 MHz, DMSO-
d6): d 161.75 (C2), 147.09 (C40), 141.32 (C4), 137.85 (C30),
137.72 (C200), 137.49 (C5), 129.11 (C6, 400, 600), 128.13 (C300, 500,
700), 121.42 (C70), 120.35 (C60), 117.89 (C3), 116.59 (C80),
110.34 (C50), 55.79 (C10), 51.78 (AOCH3), 43.21 (C100). MS
Calcd. for C20H20N2O2: 320.2. EI-MS m/z: 320.2 [M]
+.
4.3.11. 1-Benzyl-5-(((3-methoxyphenyl)amino)methyl)pyridin-
2(1H)-one (3k)
White powder, yield: 38%. M.p.: 151.3–152.9 C. 1H NMR
(400 MHz, DMSO-d6): d 7.79–7.80 (s, J= 2.4 Hz, 1H,
CH‚), 7.42–7.45 (m, J= 9.2 Hz, 1H, CH‚), 7.24–7.33 (m,
5H, ArAH), 6.91–6.95 (m, J= 8.0 Hz, 1H, ArAH), 6.40–
6.43 (m, J= 9.6 Hz, 1H, ArAH), 6.17–6.20 (m, J= 9.2 Hz,
1H, CH‚), 6.09–6.13 (m, 2H, ArAH), 6.05–6.07 (m, 1H,
ANHA), 5.05 (s, 2H, ACH2A), 3.95–3.96 (d, J= 6.0 Hz,
2H, ACH2A), 3.62 (s, 3H, AOCH3).
13C NMR (100 MHz,
DMSO-d6): d 161.31 (C2), 160.57 (C50), 149.95 (C30), 140.99
(C4), 137.75 (C200), 137.26 (C6), 129.85 (C5), 128.81 (C400, 600),
127.94(C300, 700), 127.78 (C500), 120.12 (C3), 117.17 (C70), 105.89
(C60), 101.91 (C80), 98.40 (C40), 54.86 (C10), 51.46 (AOCH3),
43.39 (C100). MS Calcd. for C20H20N2O2: 320.2. EI-MS m/z:
320.2 [M]+.
4.3.12. 1-Benzyl-5-(((3,4-dimethoxyphenyl)amino)methyl)
pyridin-2(1H)-one (3l)
Gray green crystal, yield: 43%. M.p.: 128.1–128.5 C. 1H
NMR (400 MHz, DMSO-d6): d 7.75 (s, 1H, CH‚), 7.43–
7.46 (m, J= 9.2 Hz, 1H, CH‚), 7.24–7.32 (m, 5H, ArAH),
6.66–6.68 (d, J= 8.8 Hz, 1H, ArAH), 6.39–6.42 (m,
J= 9.2 Hz, 1H, ArAH), 6.27–6.28 (m, J= 1.6 Hz, 1H,
ArAH), 6.06–6.08 (m, J= 8.4 Hz, 1H, CH‚), 5.63 (s, 1H,A
NHA), 5.05 (s, 2H, ACH2A), 3.92–3.94 (d, J= 6.0 Hz, 2H,
ACH2A), 3.62 (s, 3H, AOCH3), 3.60 (s, 3H, AOCH3).
13C
NMR (100 MHz, DMSO-d6): d 161.31 (C2), 150.10 (C50),
143.67 (C4), 140.99 (C30), 137.72 (C60), 137.10 (C200), 128.78
(C6, 400, 600), 127.89 (C300, 700), 127.75 (C500), 120.06 (C5), 117.42(C3), 114.57 (C70), 103.57 (C80), 99.29 (C40), 56.84 (C10), 55.45
(AOCH3), 51.41 (AOCH3), 44.10 (C100). MS Calcd. for
C21H22N2O3: 350.2. EI-MS m/z: 350.2 [M]
+.
4.3.13. 1-(2-Fluorobenzyl)-5-((p-tolylamino)methyl)pyridin-2
(1H)-one (3m)
White solid, yield: 37%. M.p.: 124.7–125.9 C. 1H NMR
(400 MHz, DMSO-d6): d 7.77 (s, 1H, CH‚), 7.42–7.44 (m,
J= 9.2 Hz, 1H, CH‚), 7.31–7.34 (m, 2H, ArAH), 7.11–7.16
(m, 2H, ArAH), 6.84–6.86 (m, J= 8.0 Hz, 2H, ArAH),
6.48–6.50 (m, J= 8.0 Hz, 2H, ArAH), 6.38–6.41 (m,
J= 9.2 Hz, 1H, CH‚), 5.79 (s, 1H, ANHA), 5.02 (s, 2H,
ACH2A), 3.92–3.94 (m, J= 5.6 Hz, 2H, ACH2A), 2.13 (s,
3H, ACH3).
13C NMR (100 MHz, DMSO-d6): d 161.33 (C2),
159.60 (C300), 146.22 (C30), 141.23 (C4), 137.26 (C200), 129.96
(C700), 129.88 (C50, 70), 129.59 (C60), 124.84 (C6), 124.75 (C500),
120.04 (C600), 117.45 (C5), 115.75 (C3), 115.54 (C400), 113.05
(C40, 80), 45.97 (C10), 43.63 (C100), 20.42 (ACH3). MS Calcd.
for C20H19FN2O: 322.2. EI-MS m/z: 322.2 [M]
+.
4.3.14. 1-(4-Fluorobenzyl)-5-((p-tolylamino)methyl)pyridin-2
(1H)-one (3n)
Light yellow crystal, yield: 33%. M.p.: 103.3–104.7 C. 1H
NMR (400 MHz, DMSO-d6): d 7.77 (s, 1H, CH‚), 7.42–
7.44 (m, J= 9.6 Hz, 1H, CH‚), 7.31–7.34 (m, 2H, ArAH),
7.11–7.16 (m, J= 8.4 Hz, 2H, ArAH), 6.84–6.86 (m,
J= 8.0 Hz, 2H, ArAH), 6.48–6.50 (m, J= 8.0 Hz, 2H,
ArAH), 6.38–6.41 (m, J= 9.2 Hz, 1H, CH‚), 5.79 (s, 1H,
ANHA), 5.02 (s, 2H, ACH2A), 3.92–3.94 (m, J= 9.6 Hz,
2H, ACH2A), 2.13 (s, 3H, ACH3).
13C NMR (100 MHz,
DMSO-d6): d 163.29 (C500), 161.67 (C2), 160.86 (C500), 146.34
(C30), 141.45 (C4), 137.28 (C200), 134.08 (C60), 130.52 (C50, 70),
129.85 (C300, 700), 125.15 (C6), 120.26 (C5), 117.92 (C3), 115.90
(C400, 600), 113.32 (C40, 80), 51.08 (C10), 43.74 (C100), 20.63
(ACH3). MS Calcd. for C20H19FN2O: 322.2. EI-MS m/z:
322.2 [M]+.
4.3.15. 1-(4-Methoxybenzyl)-5-((p-tolylamino)methyl)pyridin-
2(1H)-one (3o)
Light yellow crystal, yield: 25%. M.p.: 122.1–122.8 C. 1H
NMR (400 MHz, DMSO-d6): d 7.75 (s, 1H, CH‚), 7.39–
7.42 (m, J= 9.2 Hz, 1H, CH‚), 7.22–7.24 (m, J= 8.4 Hz,
2H, ArAH), 6.84–6.87 (m, J= 8.4 Hz, 4H, ArAH), 6.48–
6.50 (m, J= 8.0 Hz, 2H, ArAH), 6.36–6.39 (m, J= 9.2 Hz,
1H, CH‚), 5.78–5.81 (m, J= 6.0 Hz, 1H, ANHA), 4.96 (s,
2H, ACH2A), 3.91–3.92 (m, J= 5.6 Hz, 2H, ACH2A), 3.72
(s, 3H, AOCH3), 2.13 (s, 3H, ACH3).
13C NMR (100 MHz,
DMSO-d6): d 161.23 (C2), 158.97 (C500), 146.28 (C30), 140.82
(C4), 136.96 (C200), 129.72 (C300, 700), 129.55 (C50, 70), 124.69
(C6), 119.99 (C5), 117.18 (C3), 114.13 (C400, 600), 112.98 (C40,
80), 55.37 (C10), 50.79 (AOCH3), 43.66 (C100), 20.38 (ACH3).
MS Calcd. for C21H22N2O2: 334.1. EI-MS m/z: 334.1 [M]
+.
4.3.16. 1-Benzyl-5-(phenoxymethyl)pyridin-2(1H)-one (4a)
White crystal, yield: 46%. M.p.: 101.2–103.2 C. 1H NMR
(500 MHz, DMSO-d6): d 7.95–7.97 (s, J= 8 Hz, 1H, CH‚),
7.50–7.53 (m, J= 8 Hz, 1H, CH‚), 7.27–7.33 (m, 7H,
ArAH), 6.92–6.99 (m, 3H, ArAH), 6.44–6.47 (m, J= 8 Hz,
1H, CH‚), 5.08–5.09 (m, J= 3 Hz, 2H, ACH2A), 4.79–4.81
(m, J= 4 Hz, 2H, ACH2A).
13C NMR (125 MHz, DMSO-
Synthesis, preliminary biological evaluation and 3D-QSAR study 733d6): d 161.51 (C2), 158.55 (C30), 141.49 (C4), 139.32 (C200),
137.76 (C6), 129.94 (C50, 70), 129.02 (C400, 600), 128.14 (C300, 700),
128.00 (C500), 121.31 (C5), 120.37 (C60), 115.35 (C40, 80), 114.76
(C3), 66.75 (C10), 51.61 (C100). MS Calcd. for C19H17NO2:
291.2. EI-MS m/z: 291.2 [M]+.
4.3.17. 1-Benzyl-5-((2-fluorophenoxy)methyl)pyridin-2(1H)-
one (4b)
White crystal, yield: 48%. M.p.: 103.1–104.3 C. 1H NMR
(400 MHz, DMSO-d6): d 7.97–7.98 (s, J= 1.6 Hz, 1H,
CH‚), 7.52–7.55 (m, J= 9.2 Hz, 1H, CH‚), 7.10–7.35 (m,
8H, ArAH), 6.95–6.98 (m, 1H, ArAH), 6.46–6.48 (m,
J= 9.2 Hz, 1H, CH‚), 5.09 (s, 2H, ACH2A), 4.89 (s, 2H,
ACH2A).
13C NMR (100 MHz, DMSO-d6): d 161.68 (C2),
153.69 (C40), 151.27 (C40), 146.28 (C30), 141.68 (C4), 139.71
(C200), 137.59 (C6), 129.08 (C400, 600), 128.10 (C300, 700), 125.26
(C500), 122.10 (C5), 122.03 (C70), 120.44 (C60), 116.64 (C3),
116.47 (C50), 114.49 (C80), 68.02 (C10), 51.72 (C100). MS Calcd.
for C19H16FNO2: 309.2. EI-MS m/z: 309.2 [M]
+.
4.3.18. 1-Benzyl-5-((2-chlorophenoxy)methyl)pyridin-2(1H)-
one (4c)
White crystal, yield: 87%. M.p.: 118.0–119.1 C. 1H NMR
(400 MHz, DMSO-d6): d 7.98 (s, 1H, CH‚), 7.52–7.55 (m,
J= 9.2 Hz, 1H, CH‚), 7.41–7.43 (m, J= 8 Hz, 1H,
ArAH), 7.22–7.35 (m, 7H, ArAH), 6.95–6.99 (m,
J= 7.6 Hz, 1H, ArAH), 6.48–6.50 (d, J= 9.2 Hz, 1H), 5.10
(s, 2H, ACH2A), 4.91 (s, 2H, ACH2A).
13C NMR
(100 MHz, DMSO-d6): d 161.34 (C2), 153.66 (C30), 141.17
(C4), 139.30 (C200), 137.51 (C50), 130.29 (C6), 128.88 (C400, 600),
128.55 (C70), 128.02 (C300, 700), 127.89 (C500), 122.22 (C5),
122.08 (C40), 120.29 (C60), 115.09 (C3), 114.08 (C80), 67.72
(C10), 51.44 (C100). MS Calcd. for C19H16ClNO2: 325.1. EI-
MS m/z: 325.1 [M]+.
4.3.19. 1-Benzyl-5-((2,4-dichlorophenoxy)methyl)pyridin-2
(1H)-one (4d)
White crystal, yield: 39%. M.p.: 143.5–144.4 C. 1H NMR
(400 MHz, DMSO-d6): d 7.97 (s, 1H, CH‚), 7.57 (m, 1H,
ArAH), 7.52–7.54 (m, J= 9.2 Hz, 1H, CH‚), 7.26–7.36 (m,
7H, ArAH), 6.47–6.49 (d, J= 9.2 Hz, 1H, CH‚), 5.09 (s,
2H, ACH2A), 4.92 (s, 2H, ACH2A).
13C NMR (100 MHz,
DMSO-d6): d 161.3 (C2), 152.78 (C30), 141.22 (C4), 139.50
(C200), 137.49 (C6), 129.67 (C50), 128.90 (C400, 600), 128.36 (C70),
128.04 (C300, 700), 127.93 (C500), 125.23 (C5), 123.19 (C40),
120.35 (C60), 116.39 (C3), 113.79 (C80), 68.19 (C10), 51.46
(C100). MS Calcd. for C19H15Cl2NO2: 359.1. EI-MS m/z:
359.1 [M]+.
4.3.20. 1-Benzyl-5-((3,4-dichlorophenoxy)methyl)pyridin-2
(1H)-one (4e)
White crystal, yield: 30%. M.p.: 92.5–93.5 C. 1H NMR
(400 MHz DMSO-d6): d 7.98–7.99 (s, J= 2.4 Hz, 1H,
CH‚), 7.50–7.53 (m, J= 9.6 Hz, 2H, CH‚), 7.27–7.35 (m,
6H, ArAH), 6.99–7.03 (m, J= 9.2 Hz, 1H, ArAH), 6.45–
6.48 (d, J= 9.6 Hz, 1H, CH‚), 5.09 (s, 2H, ACH2A), 4.86
(s, 2H, ACH2A).
13C NMR (125 MHz, DMSO-d6): d 161.27
(C2), 157.79 (C30), 141.23 (C4), 139.45 (C20), 137.47 (C50),
131.86 (C70), 131.21 (C6), 128.84 (C400,600), 127.94 (C300, 700),
127.84 (C500), 122.98 (C60), 120.24 (C5), 117.14 (C3), 116.26(C40), 113.81 (C80), 67.45 (C10), 51.43 (C10). MS Calcd. for
C19H15Cl2NO2: 359.1. EI-MS m/z: 359.1 [M]
+.
4.3.21. 1-Benzyl-5-((o-tolyloxy)methyl)pyridin-2(1H)-one
(4f)
White crystal, yield: 51%. M.p.: 97.3–99.1 C. 1H NMR
(500 MHz DMSO-d6): d 7.94 (s, 1H, CH‚), 7.53–7.55 (m,
J= 9 Hz, 1H, CH‚), 7.27–7.35 (m, 5H, ArAH), 7.12–7.15
(m, J= 7.5 Hz, 2H, ArAH), 6.99–7.01 (m, J= 8 Hz, 1H,
ArAH), 6.83–6.86 (m, J= 7.5 Hz, 1H, ArAH), 6.46–6.48
(m, J= 8 Hz, 1H, CH‚), 5.09 (s, 2H, ACH2A), 4.82 (s, 2H,
ACH2A), 2.11 (s, 3H, ACH3).
13C NMR (125 MHz, DMSO-
d6): d 161.52 (C2), 156.57 (C30), 141.19 (C40), 138.88 (C200),
137.75 (C50), 130.95 (C6), 129.03 (C400, 600), 128.19 (C300, 700),
128.03 (C500), 127.34 (C70), 126.61 (C40), 121.07 (C5), 120.42
(C60), 115.04 (C3), 112.64 (C80), 66.94 (C10), 51.59 (C10), 16.52
(CH3). MS Calcd. for C20H19NO2: 305.1. EI-MS m/z: 305.1
[M]+.
4.3.22. 1-Benzyl-5-((p-tolyloxy)methyl)pyridin-2(1H)-one
(4g)
White crystal, yield: 52%. M.p.: 113.9–114.4 C. 1H NMR
(400 MHz, DMSO-d6): d 7.95–7.96 (d, J= 2 Hz, 1H, CH‚),
7.49–7.52 (m, J= 9.2 Hz, 1H, CH‚), 7.26–7.33 (m, 5H,
ArH), 7.06–7.08 (m, J= 8.8 Hz, 2H, ArAH), 6.85–6.87 (m,
J= 8.4 Hz, 2H, ArAH), 6.44–6.46 (m, J= 9.2 Hz, 1H,
CH‚), 5.09 (s, 2H, ACH2A), 4.77 (s, 2H, ACH2A), 2.23(s,
3H, ACH3).
13C NMR (125 MHz, DMSO-d6): d 161.29 (C2),
156.20 (C30), 141.26 (C4), 139.03 (C200), 137.56 (C60), 130.06
(C50, 70), 129.78 (C6), 128.81 (C400, 600), 127.93 (C300, 700), 127.79
(C500), 120.14 (C5), 115.07 (C40, 80), 114.68 (C3), 66.53 (C10),
51.38 (C10), 20.35 (ACH3). MS Calcd. for C20H19NO2: 305.1.
EI-MS m/z: 305.2 [M]+.
4.3.23. 1-Benzyl-5-((2-methoxyphenoxy)methyl)pyridin-2
(1H)-one (4h)
Light yellow crystal, yield: 69%. M.p.: 101.0–102.0 C. 1H
NMR (400 MHz, DMSO-d6): d 7.78–7.79 (s, J= 2.0 Hz, 1H,
CH‚), 7.45–7.48 (m, J= 9.2 Hz, 1H, CH‚), 7.22–7.33 (m,
5H, ArAH), 6.77–6.79 (m, J= 8.0 Hz, 1H, ArAH), 6.68–
6.72 (m, J= 7.6 Hz, 1H, ArAH), 6.51–6.55 (m, J= 8.0 Hz,
2H, ArAH), 6.38–6.40 (d, J= 8.8 Hz, 1H, CH‚), 5.05 (s,
2H, ACH2A), 4.02–4.03 (m, J= 4.8 Hz, 2H, ACH2A), 3.75
(s, 3H, ACH3).
13C NMR (100 MHz, DMSO-d6): d 161.27
(C2), 146.82 (C40), 140.84 (C30), 137.72 (C4), 137.61 (C200),
137.19 (C6), 128.78 (C400,600), 127.86 (C300, 500, 700), 127.71 (C5),
121.14 (C70), 120.12 (C60), 117.26 (C3), 116.19 (C80), 110.09
(C50), 55.57 (C10), 51.37 (AOCH3), 43.11 (C10). MS Calcd. for
C20H19NO3: 321.2. EI-MS m/z: 321.2 [M]
+.
4.3.24. 1-Benzyl-5-((4-methoxyphenoxy)methyl)pyridin-2
(1H)-one (4i)
Light yellow crystal, yield: 49%. M.p.: 100.9–101.9 C. 1H
NMR (500 MHz, DMSO-d6): d 7.93–7.94 (s, J= 2 Hz, 1H,
CH‚), 7.50–7.52 (m, J= 9.5 Hz, 1H, CH‚), 7.29–7.34 (m,
2H, ArAH), 7.25–7.29 (m, 3H, ArAH), 6.89–6.92 (m, 2H,
ArAH), 6.83–6.85 (m, 2H, ArAH), 6.44–6.46 (m,
J= 4.5 Hz, 1H, CH‚), 5.08 (s, 2H, ACH2A), 4.74 (s, 2H,
ACH2A), 3.61 (s, 3H, ACH3).
13C NMR (125 MHz, DMSO-
d6): d 161.49 (C2), 154.05 (C60), 152.44 (C30), 141.52 (C4),
734 Q. Xu et al.139.24 (C200), 137.77 (C6), 129.02 (C400, 600), 128.11 (C300, 500, 700),
128.00 (C5), 120.33 (C3), 118.24 (C50, 70), 116.49 (C40, 80),
67.40 (C10), 55.79 (AOCH3), 51.58 (C10). MS Calcd. for
C20H19NO3: 321.1. EI-MS m/z: 321.1 [M]
+.
4.3.25. 1-Benzyl-5-((3,4-dimethoxyphenoxy)methyl)pyridin-2
(1H)-one (4j)
Light yellow crystal, yield: 39%. M.p.: 124.7–125.2 C. 1H
NMR (400 MHz, DMSO-d6): d 7.93 (s, 1H, CH‚), 7.49–
7.52 (m, J= 9.6 Hz, 1H, CH‚), 7.26–7.33 (m, 5H, ArAH),
6.82–6.84 (m, J= 8.8 Hz, 1H, ArAH), 6.60–6.61 (m,
J= 1.6 Hz, 1H, CH‚), 6.45–6.50 (m, 2H, ArAH), 5.09 (s,
2H, ACH2A), 4.75 (s, 2H, ACH2A), 3.70 (s, 3H, AOCH3),
3.68 (s, 3H, AOCH3).
13C NMR (100 MHz, DMSO-d6): d
161.88 (C2), 153.00 (C30), 150.15 (C50), 143.90 (C60), 141.81
(C4), 139.20 (C200), 137.72 (C6), 129.18 (C400, 600), 128.21 (C300,
500, 700), 120.42 (C5), 115.45 (C3), 113.08 (C7), 105.51 (C80),
101.88 (C40), 67.36 (C10), 56.57 (AOCH3), 56.03 (AOCH3),
51.85 (C10). MS Calcd. for C21H21NO4: 351.1. EI-MS m/z:
351.1 [M]+.
4.3.26. 1-Benzyl-5-((3-(trifluoromethyl)phenoxy)methyl)
pyridin-2(1H)-one (4k)
Light yellow crystal, yield: 48%. M.p.: 70.3–71.9 C. 1H NMR
(500 MHz DMSO-d6): d 8.00 (s, 1H, CH‚), 7.53–7.56 (m, 1H,
CH‚), 7.50–7.53 (m, 1H, ArAH), 7.28–7.35 (m, 8H, ArAH),
6.46–6.48 (m, J= 8.0 Hz, 1H, CH‚), 5.10 (s, 2H, ACH2A),
4.92 (s, 2H, ACH2A).
13C NMR (125 MHz, DMSO-d6): d
161.51 (C2), 158.87 (C30), 141.45 (C4), 139.54 (C200), 137.71
(C50), 131.17 (C70), 129.02 (C400, 600), 128.14 (C6), 128.03 (C300,
700), 125.55 (ACF3), 123.38 (C500), 120.44 (C5), 119.68 (C3),
117.86 (C80), 114.22 (C60), 111.89 (C40), 67.34, 51.64. MS
Calcd. for C20H16F3NO2: 359.1. EI-MS m/z: 359.1 [M]
+.
4.3.27. 5-((4-Fluorophenoxy)methyl)-1-(3-methoxybenzyl)
pyridin-2(1H)-one (4l)
White powder, yield: 41%. M.p.: 98.3–100.1 C. 1H NMR
(400 MHz, DMSO-d6): d 7.94–7.95 (s, J= 2.0 Hz, 1H,
CH‚), 7.48–7.51 (m, J= 9.2 Hz, 1H, CH‚), 7.25–7.28 (m,
J= 8.4 Hz, 2H, ArAH), 7.09–7.14 (m, J= 8.8 Hz, 2H,
ArAH), 6.97–7.01 (m, 2H, ArAH), 6.88–6.90 (d, J= 8.4 Hz,
2H, ArAH), 6.43–6.45 (m, 1H, CH‚), 5.01 (s, 2H,
ACH2A), 4.77 (s, 2H, ACH2A), 3.72 (s, 3H, AOCH3).
13C
NMR (100 MHz, DMSO-d6): d 161.28 (C2), 159.06 (C50),
158.10 (C60), 155.75 (C60), 154.67 (C30), 141.20 (C4), 139.05
(C200), 129.56 (C300, 700), 120.15 (C5), 116.58 (C3), 116.50 (C50,
70), 115.99 (C40, 80), 114.22 (C400, 600), 67.29 (C10), 55.38
(AOCH3), 50.8 (C10). MS Calcd. for C20H18FNO3: 339.1. EI-
MS m/z: 339.1 [M]+.
4.3.28. 1-(3-Methoxybenzyl)-5-((p-tolyloxy)methyl)pyridin-2
(1H)-one (4m)
White powder, yield: 31%. M.p.: 118.6–120.4 C. 1H NMR
(400 MHz, DMSO-d6): d 7.93–7.93 (s, J= 2.0 Hz, 1H,
CH‚), 7.46–7.49 (m, J= 9.2 Hz, 1H, CH‚), 7.25–7.27 (m,
J= 8.8 Hz, 2H, ArAH), 7.06–7.08 (m, J= 8.4 Hz, 2H,
ArAH), 6.85–6.89 (m, J= 10.0 Hz, 4H, ArAH), 6.42–6.44
(m, J= 9.2 Hz, 1H, CH‚), 5.00 (s, 2H, ACH2A), 4.75 (s,
2H, ACH2A), 3.72 (s, 3H, AOCH3), 2.22 (s, 3H, ACH3).13C NMR (100 MHz, DMSO-d6): d 161.31 (C2), 159.07 (C50),
156.23 (C30), 141.20 (C4), 138.92 (C200), 130.11 (C300, 700),
129.78 (C60), 129.70 (C50, 70), 129.59 (C6), 120.12 (C5), 115.05
(C40, 80), 114.65 (C3), 114.23 (C400, 600), 66.64 (C10), 55.37
(AOCH3), 50.82 (C10), 20.40 (ACH3). MS Calcd. for
C21H21NO3: 335.2. EI-MS m/z: 335.2 [M]+.
4.4. Antiproliferative activity assay
The antiproliferative activity in vitro was determined using
CellTiter 961 AQueous One Solution Cell Proliferation
Assay Kit, according to operation instructions provided by
the manufacturer (Promega, Madison, WI, USA). Briefly,
A549 or NIH3T3 cell lines were cultured in 96-well plates
and allowed to grow for 24 h and subsequently treated with
all tested compounds at final concentrations of 1.5–500 lM
for 72 h. Culture medium was then removed. 20 mL of MTT
solution was added into each well of the 96-well assay plate
containing the samples in 100 mL of culture medium. The sub-
sequent incubation was performed in an atmosphere of humid-
ity, 5% CO2 at 37 C for 2 h before the cytotoxicity
assessments. Optical absorbance was recorded at 490 nm using
a Multiskan Ascent 354 microplate reader (Thermo
Labsystems, Helsinki, Finland). The absorption value was
determined by Ascent SoftwareTM (Thermo Labsystems,
Helsinki, Finland). Survival ratios are expressed in percentages
with respect to untreated cells and IC50 values were calculated
by comparison with DMSO-treated control wells by creating
the dose–response curves utilizing GraphPad PrismTM 5.0
software (GraphPad Software, Inc., La Jolla, CA, USA).
Each assay was carried out for at least three times.
4.5. 3D-QSAR model
The 3D-DSAR models were performed by QSAR software of
MOE 2014. In the present study, we have applied a novel
approach of AutoGPA to develop a 3D-QSAR model on a ser-
ies of 1,5-disubstituted-2(1H)-pyridone derivatives anti-lung
cancer agents. The procedures followed for the development
of AutoGPA models using MOE are as follows: (1) 3D struc-
tures of compounds were built using the builder tool of MOE
2014 and energy minimization was carried out using
MMFF94x force field with generalized born solvation model;
(2) The pIC50 values converted from the obtained IC50 (mM)
and conformations of active compounds were stored in a data-
base of the MOE; (3) Pharmacophore elucidation based on
conformations of dataset; (4) Generation of 3D-QSAR model
for all superimposed conformation by the AutoGPA module
in MOE; (5) Selection of the best model based on q2 values;
and (6) AutoGPA model: (Pharmacophore 3D-QSAR). The
predictive ability of 3D-QSAR modeling can be evaluated
based on the cross-validated correlation coefficient, which
qualifies the predictive ability of the models. Golbrakh
(Golbraikh and Tropsha, 2002) recommended that the criteria
(i) r2 > 0.6; (ii) q2 > 0.5 should be fulfilled for a given 3D-
QSAR model to be accepted, where r2 is the correlation coef-
ficient between the predicted and observed activities. Usually,
one can believe that the modeling complying with the above
conditions is reliable.
Synthesis, preliminary biological evaluation and 3D-QSAR study 735Acknowledgment
This work was supported by the National Natural Science
Foundation of China (No. 21172268).Appendix A. Supplementary material
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.arabjc.
2015.08.001.References
Ali, Saber, Anthonie, W., Thijo, J.N.H., Klaas, K., Anke, B., Harry, J.
M.G., 2015. Cancer Treat. Commun. 4, 23.
Azuma, A., 2010. Expert Rev. Resp. Med. 4, 301.
Burghardt, I., Tritschler, F., Opitz, C.A., Frank, B., Weller, M., Wick,
W., 2007. Biochem. Biophys. Res. Commun. 354, 542.
Comins, D.L., Lyle, R.E., 1976. J. Org. Chem. 41, 2065.
Dean, A.W., Ying, W., Matthias, B., Karen, R., Steven, O., 2014. J.
Med. Chem. 57, 7499.
Dandan, H., Yonglan, L., Bpnzhi, S., Yueting, L., Guixue, W.,
Guizhao, L., 2013. J. Mol. Graph. Model. 45, 65.
Gretchen, M.S., Yongmi, A., Zhen-Wei, C., Xiao-Tao, C., Cheryl, C.,
Lyndon, A.M.C., Jun, D., 2009. J. Med. Chem. 52, 1251.
Grattendick, K.J., Nakashima, J.M., Feng, L., Giri, S.N., Margolin, S.
B., 2008. Int. Immunopharmacol. 8, 679.
Golbraikh, A., Tropsha, A., 2002. J. Mol. Graph. Model. 20, 269.
Huang, X., Gai, Y., Yang, N., Lu, B., Samuel, C.S., Thannickal, V.J.,
Zhou, Y., 2011. Am. J. Pathol. 179, 2751.
Hynes Jr., J., Leftheri, K., 2005. Curr. Top. Med. Chem. 5, 967.
Iyer, S.N., Hyde, D.M., Giri, S.N., 2000. Inflammation 24, 477.
Jun, C., Miao-Miao, L., Bin, L., Zhuo, C., Qian-Bin, L., Li-Jian, T.,
Gao-Yun, H., 2012. Bioorg. Med. Chem. Lett. 22, 2300.
Jee, S.Y., Chulho, L., Misun, C., Hyuntae, K., Jae, H.K., Seonghwi,
C., 2015. J. Med. Chem. 58, 3512.
Krenning, G., Zeisberg, E.M., Kalluri, R.J., 2010. Cell Physiol. 225,
631.
Kenneth, R., Cutroneo, Sheryl, L.W., Jen-Fu, C., Ehrlic, H.P., 2006. J.
Cell. Biochem. 97, 1161.
Kyoung, S.K., Liping, Z., Robert, S., Zhen-Wei, C., Donna, W.,
David, K.W., Louis, J.L., 2008. J. Med. Chem. 51, 5330.Krishnan, S., Goble, J.M., Frederick, L.A., James, C.D., Uhm, J.H.,
Kaufmann, S.H., Babovic-Vuksanovic, D., 2007. J. Appl. Res. 7,
58.
Li, R., Jonas, G., David, M., James, F.B., John, J.G., Rustam, G.,
2012. J. Med. Chem. 55, 2388.
Levy, H., Murphy, A., Zou, F., Gerard, C., Klanderman, B.J.,
Schuemann, B., Lazarus, R., Garcı´a, K.C., Celedo´n, J.C., Drumm,
M., 2008. Proc. Am. Thorac. Soc. 5, 373.
Li, R., Jonas, G., David, M., James, F.B., John, J.G., Rustam, G.,
2015. J. Med. Chem. 58, 1976.
Moses, O.O., Adnan, A., Sophia, L., Li, L., Werner, J.G., 2014.
Bioorg. Med. Chem. Lett. 24, 4553.
Manoranjan, P., Sreekanth, R., Vasanthi, R., Pravin, S., 2014. J. Med.
Chem. 11, 4761.
Masahide, O., Natsuki, I., Yoshiharu, H., Masanao, I., Hiroshi, H.,
2012. Bioorg. Med. Chem. Lett. 22, 2894.
Marina, F., Madher, N.A., Qian, Z., Vincent de, P.N.N., Yukie, K.,
Sanjib, K.S., Jeremiah, B., Rylee, G., Jon, Y.T., Cheng-Wei, T.C.,
2015. J. Org. Chem. 80, 4398.
Morrow, C.J., Rapoport, H., 1974. J. Org. Chem. 39, 2116.
Nisheeth, C.D., Kiran, M.R., Vivek, V.J., 2013. Bioorg. Med. Chem.
Lett. 23, 2714.
Najma, S., Arayne, M.S., Somia, G., Sana, S., 2010. J. Mol. Struct.
975, 285.
Roldan, C., Miriam, T.-C., Daniel, T., Concepcion, Lopez, Marta, C.,
2014. Metallomics 6, 622.
Rongshi, L., Liquan, X., Tong, Z., Qi, J., Xiaoli, C., Zheng, Y.,
Danny, M., Jian, W., 2006. J. Med. Chem. 49, 1009.
Spond, J., Case, N., Chapman, R.W., Crawley, Y., Egan, R.W., Fine,
J., Hey, J.A., Kreutner, W., Kung, T., Wang, P., Minnicozzi, M.,
2003. Pulm. Pham. Ther. 16, 207.
Semple, G., Andersson, B., Chhajlani, V., Georgsson, J., Johansson,
M.J., Rosenquist, A˚., Swanson, L., 2003. Bioorg. Med. Chem. Lett.
13, 1141.
Tipparaju, Suresh K., 2008. Bioorg. Med. Chem. Lett. 18, 3565.
Wei-Ting, H., Mikael, L., Yen-Jen, W., Shih-Hwa, C., Hui-Yi, L.,
Dean-Mo, L., 2015. Mol. Pharm. 12, 1242.
Weiqiang, X., Jing, A., Shiyu, J., Zhangxing, Shi, Xia, P., Lang, W.,
2015. Eur. J. Med. Chem. 95, 302.
Weixing, Z., Jie, S., Qianbin, L., Qi, P., Jun, C., Zhuo, C., Zhaoqian,
L., Gaoyun, H., 2013. Arch. Pharm. Chem. Life Sci. 346, 654.
Ying-Rui, L., Ji-Zhuang, L.b., Pan-Pan, D., Jing, S., Bao-Xiang, Z.,
Jun-Ying, M., 2012. Bioorg. Med. Chem. Lett. 22, 6882.
Yuan, Q., Wang, R., Peng, Y., Fu, X., Wang, W., Wang, L., Zhang,
F., Peng, Z., Ning, W., Hu, G., et al, 2011. Am. J. Nephrol. 34, 181.
